These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
29. Discovery and Structural Characterization of ATP-Site Ligands for the Wild-Type and V617F Mutant JAK2 Pseudokinase Domain. McNally R; Li Q; Li K; Dekker C; Vangrevelinghe E; Jones M; Chène P; Machauer R; Radimerski T; Eck MJ ACS Chem Biol; 2019 Apr; 14(4):587-593. PubMed ID: 30763067 [TBL] [Abstract][Full Text] [Related]
30. JAK2 V617F constitutive activation requires JH2 residue F595: a pseudokinase domain target for specific inhibitors. Dusa A; Mouton C; Pecquet C; Herman M; Constantinescu SN PLoS One; 2010 Jun; 5(6):e11157. PubMed ID: 20585391 [TBL] [Abstract][Full Text] [Related]
31. STAT5 activation is critical for the transformation mediated by myeloproliferative disorder-associated JAK2 V617F mutant. Funakoshi-Tago M; Tago K; Abe M; Sonoda Y; Kasahara T J Biol Chem; 2010 Feb; 285(8):5296-307. PubMed ID: 20028972 [TBL] [Abstract][Full Text] [Related]
32. An unusual insertion in Jak2 is crucial for kinase activity and differentially affects cytokine responses. Haan C; Kroy DC; Wüller S; Sommer U; Nöcker T; Rolvering C; Behrmann I; Heinrich PC; Haan S J Immunol; 2009 Mar; 182(5):2969-77. PubMed ID: 19234192 [TBL] [Abstract][Full Text] [Related]
33. Autoinhibition of Jak2 tyrosine kinase is dependent on specific regions in its pseudokinase domain. Saharinen P; Vihinen M; Silvennoinen O Mol Biol Cell; 2003 Apr; 14(4):1448-59. PubMed ID: 12686600 [TBL] [Abstract][Full Text] [Related]
34. Mechanisms of constitutive activation of Janus kinase 2-V617F revealed at the atomic level through molecular dynamics simulations. Lee TS; Ma W; Zhang X; Giles F; Kantarjian H; Albitar M Cancer; 2009 Apr; 115(8):1692-700. PubMed ID: 19195039 [TBL] [Abstract][Full Text] [Related]
35. The effects of R683S (G) genetic mutations on the JAK2 activity, structure and stability. Li F; Guo HY; Wang M; Geng HL; Bian MR; Cao J; Chen C; Zeng LY; Wang XY; Wu QY Int J Biol Macromol; 2013 Sep; 60():186-95. PubMed ID: 23748007 [TBL] [Abstract][Full Text] [Related]
36. Phosphorylated CIS suppresses the Epo or JAK2 V617F mutant-triggered cell proliferation through binding to EpoR. Funakoshi-Tago M; Moriwaki T; Ueda F; Tamura H; Kasahara T; Tago K Cell Signal; 2017 Feb; 31():41-57. PubMed ID: 28038963 [TBL] [Abstract][Full Text] [Related]
37. Tyrosine phosphorylation of Jak2 in the JH2 domain inhibits cytokine signaling. Feener EP; Rosario F; Dunn SL; Stancheva Z; Myers MG Mol Cell Biol; 2004 Jun; 24(11):4968-78. PubMed ID: 15143188 [TBL] [Abstract][Full Text] [Related]
38. Molecular basis of JAK2 activation in erythropoietin receptor and pathogenic JAK2 signaling. Abraham BG; Haikarainen T; Vuorio J; Girych M; Virtanen AT; Kurttila A; Karathanasis C; Heilemann M; Sharma V; Vattulainen I; Silvennoinen O Sci Adv; 2024 Mar; 10(10):eadl2097. PubMed ID: 38457493 [TBL] [Abstract][Full Text] [Related]
39. Structure of the pseudokinase-kinase domains from protein kinase TYK2 reveals a mechanism for Janus kinase (JAK) autoinhibition. Lupardus PJ; Ultsch M; Wallweber H; Bir Kohli P; Johnson AR; Eigenbrot C Proc Natl Acad Sci U S A; 2014 Jun; 111(22):8025-30. PubMed ID: 24843152 [TBL] [Abstract][Full Text] [Related]